PubMed Health⌕ Search

Biomedical subjects

J Fitzpatrick

Publications and source records attributed to J Fitzpatrick.

27 records · Page 2Linked to original sources
PubMed1978

Coagulation factors in renal adenocarcinoma.

Coagulation factors, including plasma fibrinogen, serum fibrinogen-fibrin degradation products, platelet counts and prothrombin times, were studied in patients with renal adenocarcinoma. Plasma fibrinogen levels were elevated and correlated with tumor stage, disease activity and therapy. Fibrinogen-fibrin degradation product levels also were elevated, although such elevations did not correlate with other parameters. Platelet count and prothrombin times were normal. Fibrinogen may be a valuable marker of disease activity in patients with renal carcinoma. In addition, since significant intratumoral fibrin deposits have been demonstrated anticoagulants or fibrinolytic agents may enhance cytotoxic therapy and should be considered in adjunctive chemotherapeutic protocols.

Adenocarcinoma↗
PubMedDate not supplied

The effect of vinblastine on CFU-E in normal and W anaemic mice.

Using a plasma clot technique, we studied the comparative levels of in vitro erythroid colony forming units (CFU-E) of normal and W anaemic mice following intravenous (IV) injection of 6.25 mg/kg of vinblastine (VBL). Mice used in this study were C57Bl/6J, WBB6F1, (+/+,Wv/+ and W/Wv). CFU-E content was looked at on day 0, 1, 3, 5, 7 and 10 following IV VBL. The CFU-E content of bone marrow (BM) and spleen was adequate prior to VBL treatment in all four mouse strains tested. We found IV VBL resulted in a significant rebound of CFU-E production in spleens of all four mouse strains. Most CFU-E production occurred on days 7 and 10 post VBL. The total CFU-E content of BM was not significantly affected by VBL in C57Bl/6J, WBB6F1, +/+ and Wv/+ mice. However, a significant reduction of total CFU-E was seen in the BM of WBB6F1, W/Wv mice. This plus the fact that increased CFU-E is seen in the spleen of all mouse strains including W/Wv suggests that there may be differing cellular or environmental factor(s) in different hematological organs controlling CFU-E of the W/Wv mouse.

Anemia↗
PubMedDate not supplied

Enhancement of the indirect anti-platelet antibody test and its application to platelet immunology.

Comparisons in the same patients of platelet-bound anti-platelet antibody (APA) levels (direct test) with serum APA levels (indirect test) frequently do not give the same results. Indirect test results frequently are negative or marginally elevated even though platelet-bound antibody is greatly increased on direct testing. The most likely cause for these differences between the two tests is insufficient binding of serum antibody to test platelets in vitro. In an effort to enhance in vitro antibody binding, we examined four test modifications affecting platelet attachment. Rabbit anti-human platelet antisera (absorbed with their specific human donor leukocytes to remove HLA- and granulocyte-specific antibodies) were combined under various conditions with human platelets and tested in a modified antiglobulin consumption test utilizing rabbit IgG. The test conditions varied: incubation time of the serum APA-platelet mixture at 37 degrees C; age of the test platelet pool; ionic strength of the mixture (varied through incorporation of a low-ionic-strength solution (LISS); and vortex agitation for 30 seconds prior to the addition of sera. Optimal attachment in standard phosphate-buffered saline took place in 60 minutes using test platelets stored for either 3 or 30 days, and yielded mean values for rabbit immune sera of 9.9 fg of IgG per platelet. Preincubation controls yielded a mean of 0.7 to 1.5 fg per platelet. Incorporation of LISS or vortexing of test platelets did not affect the results of control, but both modifications substantially increased test values of immune sera to 15.8 and 17.3 fg of IgG per platelet, respectively. Combining LISS with vortexing did not further increase values.

Animals↗
PubMedDate not supplied

From taxonomy I to taxonomy II.

Taxonomic development in nursing, although still in its infancy, is progressing. Taxonomy development has moved beyond subjective placement of diagnoses into categories based on an "expert" opinion alone. The taxonomy of nursing diagnoses is entering a new era whereby the assumptions and classification rules for Taxonomy I--Revised are being investigated. Alternative taxonomic structures require careful scrutiny and comparison to establish whether one structure will meet the needs of the profession or whether multiple structures of nursing diagnoses relative to outcomes are required. As members within the discipline become more sophisticated in approaches to taxonomic development, methods of handling taxonomic problems, such as varying levels of abstraction and taxonomic affinity, will be discerned.

Humans↗